PegIFNa/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

PegIFNa/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24

Saadoun D, M R-R, Thibault V, et al. PegIFNa/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, et al. Ann Rheum Dis. 2014;73(5):831-837.

Publication Type:

Journal Article

Authors:

Saadoun, D.; Resche-Rigon M; Thibault, V.; et, al

Source:

Ann Rheum Dis, Volume 73, Issue 5, p.831-837 (2014)

Keywords:

administration & dosage, adverse effects, Aged, analogs & derivatives, Antiviral Agents, boceprevir, clinical trial, Cohort Studies, complications, Cryoglobulinemia, Depression, drug therapy, Drug Therapy,Combination, Erythropoietin, Female, France, HCV, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, interferon, Interferon-alpha, Internal Medicine, Male, Medicine, methods, Middle Aged, Neutropenia, nonresponder, Oligopeptides, Paris, Patients, peginterferon, pegylated, pegylated interferon, Polyethylene Glycols, Proline, protease inhibitor, Protease Inhibitors, Proteins, Recombinant Proteins, Research, Research Support, Ribavirin, Rna, Safety, Standard of Care, Telaprevir, therapy, Thrombocytopenia, Time, treatment, Treatment Outcome, Vasculitis, virology, Women

Notes:

PMC3995244

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/23606708

Export Citation:

RIS Format

Top